Table 2.

Use of Inotuzumab ozogamicin and infectious events

References	Study	Monotherapy/combination	Patients (n°)	Phase of disease	Infections	Febrile neutropenia/FUO	Pneumonia	Sepsis	Bacterial infection	Fungine	Viral
Kantarjian et al. [18]	Phase 2	Monotherapy	49, adults and children	Relapsed/refractory		8 (16%)	5 (10%)	8 (16%)		2 (4%)	5 (10%)
Kantarjian et al. [19]	Phase 3	Monotherapy verses standard PCT	139, adults	Relapsed/refractory	29 (21%)	16 (12%)	5 (4%)	6 (4%)	C. Difficile 2 (1%)	0
Jabbour et al. [20]	Phase 2	Combined*	48, adults	Relapsed/refractory	32 (67%)			1 (2%)
Kantarjian et al. [21]	Phase 2	Combined with low intensity PCT**	52, adults	Onset	48 (92%)
DeAngelo et al. [22]	Phase 3	Monotherapy verses standard PCT	162, adults	Relapsed/refractory		9 (17%) 17 (22%) 16 (53%)	2 (4%) 2 (3%) 1 (3%)	1 (2%) 1 (1%) 0
Brivio et al. [23]	Phase 1	Monotherapy	25, pediatric	Relapsed/refractory (pediatric)		8 (32%)					Rhinitis: 3 (12%)

*Combined with mini-hyper-CVD with or without Blinatumomab

**Mini-hyper-CVD